Cipla share price
NSE: CIPLABSE: 500087Pharmaceuticals & BiotechnologyLarge Cap
Cipla Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1983 on BSE, Feb 1995 on NSE
Last close ₹1,358.00down ₹7.60 (0.56%)BSE ₹1,357.00
Share price at the NSE close on 29 Oct 2026. Previous close ₹1,365.60.
29 Oct: open ₹1,357.70, high ₹1,372.50, low ₹1,347.00
52-week range of traded prices to 29 Oct 2026
₹1,165.70Low, 2 Apr 2026₹1,593.30High, 30 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,09,709 Cr99th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 37.87
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.10
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.96%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 8.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 9.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 11,41,23054.3% delivered
About Cipla
Cipla Limited is a Mumbai-based drug maker that develops, makes and sells medicines, including inhalers and other treatments for lung diseases, generic and complex generic medicines, consumer health products and active pharmaceutical ingredients (APIs, the drug substance inside a medicine).123 Its home markets are India, South Africa and North America, and it also sells in other emerging markets and Europe.45
Its business is organised into One India, which covers branded prescription medicines, trade generics through Cipla Pharma and Life Sciences and consumer health through Cipla Health; North America; One Africa, which covers South Africa, North Africa, sub-Saharan Africa and Cipla Global Access; and Emerging Markets and Europe.675 The company names respiratory, antiretroviral (HIV), urology, cardiology, anti-infective and central nervous system medicines as its strengths.4 In India it also sells medicines licensed from other drug makers, including Eli Lilly's Yurpeak (tirzepatide) for type 2 diabetes and weight management, MannKind's inhaled insulin Afrezza and brands from Pfizer.85 It has more than 31,000 permanent employees and workers in 18 countries.9 It runs 48 manufacturing facilities that comply with current good manufacturing practice (cGMP, the standard drug regulators inspect against) in India, the US, South Africa, China and Morocco.1011
The company was incorporated in 1935.3 It acquired Inzpera Healthsciences, adding paediatric and wellness products, on 4 Dec 2025.125 Achin Gupta has been Managing Director and Global Chief Executive Officer since 1 Apr 2026.13 The promoter and promoter group held 29.21% of the shares on 31 Mar 2026.14
Cipla key points
Results
- In the quarter to Jun 2026, consolidated revenue was ₹7,119 crore, the highest for any April to June quarter; EBITDA (profit before interest, tax, depreciation and amortisation) was ₹1,192 crore, a 16.7% margin, and profit after tax ₹789 crore.1516
- A year earlier, in the quarter to Jun 2025, consolidated revenue was ₹6,957 crore, EBITDA ₹1,778 crore, a 25.6% margin, and profit after tax ₹1,298 crore.1716
- In the quarter to Jun 2026, consolidated revenue rose 2% on a year earlier; from 1 Apr 2026 some marketing expenses are deducted from revenue, not costs, and the company said growth would be about 4% with the previous year adjusted the same way.1819
- In the year to Mar 2026, consolidated revenue was ₹28,163 crore, EBITDA ₹5,925 crore and profit after tax ₹3,879 crore.2021
Market position
- In India it is the largest drug maker by units, the only one above 2 billion in the year to Jun 2026, and first in respiratory medicines, with over 25% in the year to Mar 2026.2223
- Its Foracort inhaler is India's top-ranked respiratory brand and the first brand there to pass ₹1,000 crore in sales; 33 of its brands each sell over ₹100 crore a year.2425
- In the US it ranks first in albuterol (an asthma reliever) metered-dose inhalers (pressurised puffers), with a 21% share in June 2026.26
Business segments
- Share of revenue by business27
Item quarter to Jun 2026 One India 48% North America 22% One Africa 14% Emerging Markets and Europe 14% API and others 2% - One India had revenue of ₹3,452 crore in the quarter to Jun 2026, its highest for any quarter, up 12% on a year earlier; in the year to Mar 2026 its revenue passed ₹12,500 crore.282930
- North America had revenue of $162 million in the quarter to Jun 2026, when it launched generic Ventolin, an asthma inhaler, as the first approved equivalent, with 6 months of US exclusivity.312332
- In the quarter to Jun 2026, One Africa had revenue of $103 million, up 1% on a year earlier, and Emerging Markets and Europe $106 million, up 5%.33
Plants and capacity
- Capacity a year, by product34
Item year to Mar 2026 Tablets and capsules 25 billion units Respules (liquid doses for nebulisers) 569 million units Metered-dose inhalers 150.3 million units Dry powder inhalers (breath-activated) 3.4 million units APIs 792 tonnes - Capital spending was ₹3,079 crore in the year to Mar 2026; approved investments over 2 years exceed ₹4,000 crore, including a respiratory API plant at Kurkumbh and an inhaler plant at Fall River, Massachusetts.3536
Research and development
- R&D spending was ₹1,974 crore in the year to Mar 2026 and ₹486 crore, 6.8% of revenue, in the quarter to Jun 2026, across 6 centres in Maharashtra, Karnataka, New York and Germany.373839
- On 30 Jun 2026 its US portfolio and pipeline, counting InvaGen's, PEPFAR (a US aid programme) and partners' applications, held 278 applications for generic (ANDA) and new (NDA) medicines: 186 approved, 44 tentatively approved and 48 under approval.40
- As of its annual report of 1 Jun 2026, its biosimilar (near-copy of a biologic medicine) joint venture with Kemwell Biopharma, Aspergen Inc., had filed to start human studies of ASP100 in the US and a clinical trial application for ASP200 in India.41
What the company expects
- On its earnings call of 23 Jul 2026, the company said it expects an EBITDA margin of 18.5% to 20% for the year to Mar 2027, depending on approvals and new launches, and that the current margin is below its steady state.4243
- On its earnings call of 23 Jul 2026, the company said approval of 4 significant US launches in the rest of the year, 3 respiratory including generic Advair, would give line of sight to a $1 billion exit rate (yearly revenue pace at year end).4445
Recent events
- On 3 Sep 2026, its US subsidiary InvaGen took exclusive US rights to QL2107, Qilu Pharmaceutical's biosimilar of the cancer drug Keytruda (pembrolizumab), which Qilu develops and supplies.46
- On 31 Aug 2026, it licensed from SBP Group's CTTQ exclusive rights to TQB2102, an antibody-drug conjugate (an antibody carrying a drug to cancer cells) being evaluated in HER2-expressing cancers, for India, South Africa and 5 other emerging markets.47
- On 27 Jul 2026, the US FDA approved its generic Advair Diskus, for asthma and chronic obstructive pulmonary disease, its first dry powder inhaler from its US plants; the company cites IQVIA data putting the US market at about $908 million.4849
Litigation and regulatory matters
- A follow-up US FDA inspection of the Pithampur plant in India, from 17 to 25 Aug 2026, ended with 7 observations on Form 483 (the inspectors' list of issues); the company's documents give no outcome.50
Last updated
All 50 sources, each with its page
- 1. Annual report, 1 Jun 2026, page 150
- 2. Annual report, 1 Jun 2026, page 159
- 3. Annual report, 1 Jun 2026, page 185
- 4. Exchange filing, 3 Sep 2026, page 2
- 5. Annual report, 1 Jun 2026, page 33
- 6. Annual report, 1 Jun 2026, page 153
- 7. Investor presentation, 23 Jul 2026, page 5
- 8. Annual report, 1 Jun 2026, page 43
- 9. Annual report, 1 Jun 2026, page 40
- 10. Annual report, 1 Jun 2026, page 75
- 11. Annual report, 1 Jun 2026, page 76
- 12. Annual report, 1 Jun 2026, page 165
- 13. Annual report, 1 Jun 2026, page 235
- 14. Exchange filing, 19 Aug 2026, page 6
- 15. Investor presentation, 23 Jul 2026, page 4
- 16. Investor presentation, 23 Jul 2026, page 5
- 17. Investor presentation, 23 Jul 2026, page 5
- 18. Earnings call, 23 Jul 2026, page 5
- 19. Earnings call, 23 Jul 2026, page 6
- 20. Annual report, 1 Jun 2026, page 41
- 21. Annual report, 1 Jun 2026, page 185
- 22. Earnings call, 23 Jul 2026, page 4
- 23. Annual report, 1 Jun 2026, page 151
- 24. Annual report, 1 Jun 2026, page 43
- 25. Earnings call, 23 Jul 2026, page 4
- 26. Earnings call, 23 Jul 2026, page 4
- 27. Investor presentation, 23 Jul 2026, page 5
- 28. Investor presentation, 23 Jul 2026, page 6
- 29. Earnings call, 23 Jul 2026, page 3
- 30. Annual report, 1 Jun 2026, page 33
- 31. Earnings call, 23 Jul 2026, page 4
- 32. Earnings call, 23 Jul 2026, page 13
- 33. Investor presentation, 23 Jul 2026, page 4
- 34. Annual report, 1 Jun 2026, page 75
- 35. Annual report, 1 Jun 2026, page 40
- 36. Annual report, 1 Jun 2026, page 34
- 37. Annual report, 1 Jun 2026, page 40
- 38. Investor presentation, 23 Jul 2026, page 5
- 39. Annual report, 1 Jun 2026, page 83
- 40. Investor presentation, 23 Jul 2026, page 11
- 41. Annual report, 1 Jun 2026, page 87
- 42. Earnings call, 23 Jul 2026, page 16
- 43. Earnings call, 23 Jul 2026, page 18
- 44. Earnings call, 23 Jul 2026, page 5
- 45. Earnings call, 23 Jul 2026, page 8
- 46. Exchange filing, 3 Sep 2026, page 2
- 47. Exchange filing, 31 Aug 2026, page 2
- 48. Exchange filing, 27 Jul 2026, page 2
- 49. Exchange filing, 27 Jul 2026, page 1
- 50. Exchange filing, 25 Aug 2026, page 1
Results
Consolidated; ₹ crore.Cipla quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −0.7%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −46.8%
Quarter to Sep 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹7,404 Crup 4.00%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹852 Crup 8.40%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 11.5%
Revenue by quarter
Peak revenue ₹7,589 Cr, quarter to Sep 2025; lowest ₹6,541 Cr, quarter to Mar 2026
Net profit by quarter, a loss in red
| ₹ crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7,073 | 6,730 | 6,957 | 7,589 | 7,074 | 6,541 | 7,119 | 7,404 |
| Net profit | 1,575 | 1,214 | 1,292 | 1,353 | 674 | 543 | 786 | 852 |
| Net margin | 22.3% | 18.0% | 18.6% | 17.8% | 9.5% | 8.3% | 11.0% | 11.5% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹28,163 Crup 2.23%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹3,862 Crdown 26.71%
- Net margin
- 13.7%
Revenue by year
Peak revenue ₹28,163 Cr, year to Mar 2026; lowest ₹14,630 Cr, year to Mar 2017
Net profit by year, a loss in red
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14,630 | 15,219 | 16,362 | 17,132 | 19,160 | 21,763 | 22,753 | 25,774 | 27,548 | 28,163 |
| Net profit | 1,006 | 1,417 | 1,492 | 1,500 | 2,389 | 2,547 | 2,833 | 4,154 | 5,269 | 3,862 |
| Net margin | 6.9% | 9.3% | 9.1% | 8.8% | 12.5% | 11.7% | 12.5% | 16.1% | 19.1% | 13.7% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceutical and related products, which carries all its revenue.
Valuation
Today, against the company's own history.Cipla PE ratio and valuation
Price to earnings
At or below today's level on 83% of 2,233 trading days over the last 10 years.
LowestHighest
Its median29.97Industry median28.22
Price to book
At or below today's level on 20% of 1,978 trading days since Nov 2018.
LowestHighest
Its median3.82Industry median2.97
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 86% of 2,458 trading days over the last 10 years.
LowestHighest
Its median0.55%Industry median0.48%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −14.1% | −26.4% | +15.4% | 1.1% |
| 3 years | +11.8% | +11.4% | −0.6% | 1.0% |
| 5 years | +9.4% | +10.0% | −1.4% | 0.9% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual fund holdings
338 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 170 of the 212 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 5 more funds filed their first portfolio on record, holding it.All 338 funds holding Cipla
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 4
- AddedAdded. Funds that held more shares than at the end of the month before.
- 114
- CutCut. Funds that held fewer shares than at the end of the month before.
- 98
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 117
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 7
| Fund | |||
|---|---|---|---|
 HDFC Flexi Cap FundHDFC Mutual Fund | 1,99,02,429 | 2.47% | ₹2,678.9 Cr |
 Parag Parikh Flexi Cap FundPPFAS Mutual Fund | 1,43,51,629 | 1.33% | ₹1,931.7 Cr |
 SBI Nifty 50 ETFSBI Mutual Fund | 1,09,15,593 | 0.72% | ₹1,469.2 Cr |
 ICICI Prudential Value FundICICI Prudential Mutual Fund | 57,30,736 | 1.35% | ₹771.4 Cr |
| SBI ELSS Tax Saver FundSBI Mutual Fund | 47,56,637 | 2.13% | ₹640.2 Cr |
| HDFC Focused FundHDFC Mutual Fund | 47,33,207 | 2.40% | ₹637.1 Cr |
 Nippon India Pharma FundNippon India Mutual Fund | 40,95,054 | 6.01% | ₹551.2 Cr |
| Nippon India Large Cap FundNippon India Mutual Fund | 40,86,211 | 1.07% | ₹550.0 Cr |
| SBI Contra FundSBI Mutual Fund | 38,36,985 | 1.15% | ₹516.5 Cr |
| ICICI Prudential Large Cap FundICICI Prudential Mutual Fund | 37,54,082 | 0.66% | ₹505.3 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 30 Oct 2025.Cipla insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Others: no market trade
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Cipla competitors and peers
Pharmaceuticals, 215 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Cipla in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Torrent PharmaceuticalsTORNTPHARM | 1,74,208 | 82.02 | 9.48 | +42.1% | −0.7% | 15.8% | 12.0% | 0.83% |
 Laurus LabsLAURUSLABS | 1,21,246 | 90.49 | 20.01 | +23.0% | +95.9% | 24.7% | 21.8% | 0.09% |
 Zydus LifesciencesZYDUSLIFE | 1,18,144 | 26.18 | 4.36 | +21.1% | −1.3% | 17.7% | 15.9% | 0.08% |
 Dr. Reddy's LaboratoriesDRREDDY | 1,12,264 | 40.10 | 2.89 | −3.5% | −51.5% | 7.5% | 6.0% | 0.59% |
 Mankind PharmaMANKIND | 1,01,993 | 45.36 | 5.80 | +13.3% | +28.4% | 13.7% | 13.6% | 0.00% |
 Aurobindo PharmaAUROPHARMA | 95,507 | 25.73 | 2.52 | +9.1% | +9.5% | 10.5% | 11.5% | 0.00% |
 LupinLUPIN | 90,996 | 16.46 | 4.05 | +28.2% | +49.5% | 27.9% | 28.2% | 0.90% |
 Glenmark PharmaceuticalsGLENMARK | 66,012 | 36.72 | 6.28 | +32.9% | +138.4% | 18.6% | 39.8% | 0.11% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Cipla dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹16.00 a share, year to Mar 2025.
| Ex-date | Type | Per share |
|---|---|---|
| 5 Jun 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹13.00 |
| 27 Jun 2025 | Final | ₹13.00 |
| 27 Jun 2025 | Special | ₹3.00 |
| 2 Aug 2024 | Final | ₹13.00 |
| 21 Jul 2023 | Final | ₹8.50 |
| 8 Aug 2022 | Final | ₹5.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Cipla announcements
Oct 2026
29 Oct · Disclosure
27 Oct · Updates
27 Oct · Results
23 Oct · General Updates
Cipla share price by year
Each calendar year to 2025.Cipla share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,511.30 | −1.2% | 1,663.60 | 1,384.70 |
| 2024 | 1,529.00 | +22.7% | 1,680.50 | 1,251.00 |
| 2023 | 1,246.30 | +15.8% | 1,271.50 | 862.35 |
| 2022 | 1,075.95 | +14.0% | 1,173.40 | 867.45 |
| 2021 | 944.10 | +15.1% | 987.60 | 755.15 |
| 2020 | 819.95 | +71.5% | 833.20 | 374.70 |
| 2019 | 478.20 | −7.9% | 578.70 | 408.25 |
| 2018 | 519.50 | −14.6% | 672.80 | 512.55 |
| 2017 | 608.50 | +7.0% | 654.80 | 488.90 |
| 2016 | 568.80 | −12.5% | 655.35 | 464.90 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 28 Oct 2026 | 1,335.20 | 1,368.20 | 1,327.10 | 1,365.60 | 1,357.41 | 9,97,121 | 49.2% |
| 27 Oct 2026 | 1,352.10 | 1,372.70 | 1,319.00 | 1,350.00 | 1,345.83 | 40,78,811 | 37.7% |
| 26 Oct 2026 | 1,336.60 | 1,360.00 | 1,330.00 | 1,355.00 | 1,346.10 | 15,48,428 | 49.7% |
| 23 Oct 2026 | 1,332.40 | 1,338.00 | 1,314.10 | 1,338.00 | 1,325.50 | 13,23,900 | 58.1% |
| 22 Oct 2026 | 1,302.00 | 1,330.90 | 1,296.40 | 1,330.90 | 1,319.11 | 6,38,943 | 54.1% |
| 21 Oct 2026 | 1,324.10 | 1,337.50 | 1,308.30 | 1,314.00 | 1,314.43 | 12,38,869 | 68.1% |
| 19 Oct 2026 | 1,322.00 | 1,339.00 | 1,321.60 | 1,324.10 | 1,327.89 | 13,87,215 | 68.6% |
| 16 Oct 2026 | 1,335.00 | 1,337.50 | 1,315.10 | 1,325.10 | 1,324.45 | 8,50,284 | 62.5% |
| 15 Oct 2026 | 1,311.60 | 1,336.40 | 1,310.60 | 1,328.00 | 1,327.20 | 13,71,747 | 64.8% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- CIPLA
- BSE code
- 500087
- ISIN
- INE059A01026
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.cipla.com
- CIN
- L24239MH1935PLC002380
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1935
- Registered office
- Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400013, Maharashtra
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 50, Nifty 100, BSE 100, Nifty 200, BSE 200, Nifty 500